Role of SGLT2I in Patients With Myocardial Infarction

Dongying Zhang

Status: Enrolling

Conditions: Diabetes Mellitus; Myocardial Infarction

Treatments: Drug: SGLT2 inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT06245980

20230515

Details and patient eligibility

About

Role of sglt2I in diabetic patients with myocardial infarction

Enrollment: 1,200 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Acute myocardial infarction patients
2. Type 2 diabetics.

Exclusion criteria

1. Patients undergoing coronary artery bypass grafting (CABG).
2. Severe valvular heart disease.
3. Contraindications of secondary medical preventive therapy for myocardial infarction, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins.
4. Previously used SGLT2i.
5. Severe hepatic and renal insufficiency.

Trial design

1,200 participants in 2 patient groups

With SGLT2I

Treatment:

Drug: SGLT2 inhibitor

Without SGLT2i